Core Insights - Functional Brands Inc. reported strong financial growth in Q3 2025, with significant achievements that position the company for accelerated growth [2][3] - The company successfully completed its direct listing on the Nasdaq Capital Market under the symbol MEHA, which is seen as a validation of its business model and a foundation for future expansion [2] - The P2i by Kirkman prenatal supplement became the first to align with FIGO's transparency standards and comply with California's SB 646 QR-code disclosure law ahead of the 2027 deadline [3] Financial Performance - Revenue for Q3 2025 reached $1.7 million, marking a 21.4% increase compared to Q3 2024, driven primarily by growth in direct-to-consumer sales [8] - Gross profit increased by 28.1% year-over-year, with the gross profit margin improving by 310 basis points to 57.8% due to higher revenue and better cost control [8] - The company reported a net income of $0.3 million or $0.04 per diluted share, a turnaround from a net loss of $0.3 million in the prior year [8] Balance Sheet Highlights - As of September 30, 2025, total assets amounted to $8.23 billion, an increase from $7.17 billion at the end of 2024 [7] - Current assets rose to $4.21 billion, up from $2.86 billion at the end of 2024, with cash increasing significantly to $1.01 million [7] - Total liabilities increased to $7.63 billion from $7.29 billion, with current liabilities also rising to $5.70 billion [7] Strategic Initiatives - The company formed a partnership with Market Performance Group to enhance the growth of its Kirkman brand across eCommerce and digital channels [3] - Functional Brands is focused on acquiring and growing science-based consumer brands, with a commitment to providing high-quality wellness solutions [4]

If you did a direct listing, I don't think you would have direct listed at a 100 bucks a share. It might have been 39 or 40. The weird kind of thing is I'm going to, how do you put this.Say that it may well be that these random weird pops every once in a while are just like a natural phenomenon like earthquakes, right. They just randomly happen because it's not like if you did a direct listing, people would have said, "Yeah, I think I should pay 80 times rune revenues for this puppy." It would have been the ...

VenHub plans to undertake a direct listing on a US exchange after the developer of fully automated retail stores abandoned an earlier plan to go public by merging with a blank-check firm https://t.co/GBZBQQqYRK ...

IPO & Listing - Direct listings are lining up, indicating a potential increase in companies choosing this method to go public [1] - Klook is considering a US IPO, suggesting expansion and access to US capital markets [1] Mergers & Acquisitions - HPE (Hewlett Packard Enterprise) signs pact with activist Elliott, potentially influencing HPE's strategic direction and M&A activities [1]

Market Trends - US IPOs are reviving, along with the return of blank-check companies [1] - Direct listings, a previously unpopular method for companies to go public, are gaining renewed interest [1]

IPO Considerations - The quality of the underlying asset and its potential value in 5 years are key factors [1] - Liquidity in the IPO is important, specifically the float size (millions or billions) [1] - Percentage of floating shares and lockup terms are crucial for participation [2] Key IPO Factors - Larger IPOs are preferred, enabling the acquisition of a significant position [2] - A higher percentage of publicly floating shares is better for price discovery [3] - A higher percentage of publicly floating shares reduces volatility and susceptibility to manipulation [3] Lockup Periods - The presence and duration of a lockup period are important considerations [4] - Direct listings may not have lockup periods, potentially leading to faster price discovery [4] - A minimum of 20% float is preferred to avoid volatility [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FibroBiologics, Inc. As filed with the Securities and Exchange Commission on January 22, 2024. Registration No. 333-275361 Delaware 2834 86-3329066 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 455 E. Medical Center Blvd. Suite 300 Houston, T ...